SARS-CoV-2/COVID-19 in multiple sclerosis patients receiving disease-modifying therapy

At the end of 2019, the COVID-19 pandemic began, which at the time of writing continues to be a serious problem for many areas of medicine, including neurology. Since patients with multiple sclerosis (MS) often exhibit motor disability and receive disease-modifying therapy (DMT), which has an immuno...

Descripción completa

Detalles Bibliográficos
Autores principales: Adamczyk-Sowa, Monika, Mado, Hubert, Kubicka-Bączyk, Katarzyna, Jaroszewicz, Jerzy, Sobala-Szczygieł, Barbara, Bartman, Wojciech, Sowa, Paweł
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7831713/
https://www.ncbi.nlm.nih.gov/pubmed/33388661
http://dx.doi.org/10.1016/j.clineuro.2020.106451

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7831713/
https://www.ncbi.nlm.nih.gov/pubmed/33388661
http://dx.doi.org/10.1016/j.clineuro.2020.106451

Ejemplares similares